|
21 Sep 2025 |
Dr. Reddy's Labs
|
Consensus Share Price Target
|
1321.70 |
1285.13 |
- |
-2.77 |
hold
|
|
|
|
|
11 May 2023
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1321.70
|
4500.00
|
4532.00
(-70.84%)
|
Target met |
Sell
|
|
|
|
|
11 May 2023
|
Dr. Reddy's Labs
|
SMC online
|
1321.70
|
|
4532.00
(-70.84%)
|
Pre-Bonus/ Split |
Results Update
|
|
|
|
|
11 May 2023
|
Dr. Reddy's Labs
|
Axis Direct
|
1321.70
|
5100.00
|
4532.00
(-70.84%)
|
Target met |
Hold
|
|
|
Company Outlook & Guidance: Q4FY22 results were week. However, we believe DRRD's strategy of in investing various businesses may provide growth in the long term.
|
|
11 May 2023
|
Dr. Reddy's Labs
|
BOB Capital Markets Ltd.
|
1321.70
|
4900.00
|
4532.00
(-70.84%)
|
Target met |
Hold
|
|
|
Q4 broadly in line as revenue/EBITDA grew 16%/35% YoY (-7%/-23% QoQ), albeit aided by one-offs
|
|
07 Feb 2023
|
Dr. Reddy's Labs
|
Geojit BNP Paribas
|
1321.70
|
5166.00
|
4440.25
(-70.23%)
|
Target met |
Buy
|
|
|
|
|
27 Jan 2023
|
Dr. Reddy's Labs
|
ICICI Securities Limited
|
1321.70
|
5131.00
|
4200.95
(-68.54%)
|
Target met |
Buy
|
|
|
Dr. Reddy’s Laboratories’ (DRL) Q3FY23 reported performance exceeded our and consensus estimates, largely driven by higher-than-estimated sales of Revlimid in Q3FY23. This resulted in 27.3% YoY growth in revenue to Rs67.7bn (I-Sec: Rs58.6bn).
|
|
27 Jan 2023
|
Dr. Reddy's Labs
|
Axis Direct
|
1321.70
|
5100.00
|
4314.00
(-69.36%)
|
Target met |
Buy
|
|
|
We recommend a BUY on the stock.
|
|
27 Jan 2023
|
Dr. Reddy's Labs
|
ICICI Direct
|
1321.70
|
5210.00
|
4314.00
(-69.36%)
|
Target met |
Buy
|
|
|
|
|
26 Jan 2023
|
Dr. Reddy's Labs
|
BOB Capital Markets Ltd.
|
1321.70
|
4700.00
|
4200.95
(-68.54%)
|
Target met |
Hold
|
|
|
Q3 revenue growth strong at 27% YoY to Rs 67.7bn, supported by US contribution and launches
|
|
26 Dec 2022
|
Dr. Reddy's Labs
|
Axis Direct
|
1321.70
|
4750.00
|
4248.60
(-68.89%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a target price of Rs 4,750/share, implying an upside of 10% from the CMP.
|